Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05066308 · ClinicalTrials.gov registry record · Phase 2
Cannabidiol for Reduction of Brain Neuroinflammation
A Phase 2 study of Depressive Symptoms and Back Pain, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT05066308 is a Phase 2 study of Depressive Symptoms and Back Pain that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 80 participants, below the 260-participant average among 60 other Depressive Symptoms trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05066308, a Phase 2 study of Depressive Symptoms and Back Pain, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will investigate whether cannabidiol (CBD), the primary centrally and peripherally active non-intoxicating compound in the cannabis plant, exerts anti-neuroinflammatory effects in patients with chronic low back pain (cLBP) with or without mild-to-moderate depression.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG CBD
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2022-01-04 |
| Est. Completion | 2026-12-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05066308
The ClinicalTrials.gov registry entry for NCT05066308 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 260-participant average among 60 other Depressive Symptoms trials with a reported enrollment target (69% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Depressive Symptoms appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05066308 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05066308 about?
NCT05066308 is a clinical study titled "Cannabidiol for Reduction of Brain Neuroinflammation". This study will investigate whether cannabidiol (CBD), the primary centrally and peripherally active non-intoxicating compound in the cannabis plant, exerts anti-neuroinflammatory effects in patients with chronic low back pain (cLBP) with or without mild-to-moderate depression.
What is the current status of trial NCT05066308?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2022-01-04. Estimated completion is 2026-12-15.
What conditions does trial NCT05066308 study?
This clinical trial studies the following conditions: Depressive Symptoms, Back Pain.
What interventions are being tested in trial NCT05066308?
The interventions under investigation include: Placebo (OTHER), CBD (DRUG).
Who is sponsoring clinical trial NCT05066308?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05066308 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depressive Symptoms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial
ACTIVE NOT RECRUITING · Phase 2
-
Beating the Blues for Your Heart
COMPLETED · Phase 2
-
Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD)
COMPLETED · Phase 2
-
Acute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A)
RECRUITING · Phase 4
-
Caregiver Stress and Sleep Study
RECRUITING · NA
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.